An ongoing phase III, sham-controlled study is investigating intravitreal sirolimus 440 μg (Opsiria, Santen) for the treatment of active, non-infectious uveitis of the posterior segment, said Steven Yeh, MD.
The STOP-Uveitis Study has shown that intravenous infusions of the humanized monoclonal antibody tocilizumab are effective as a novel therapeutic management approach for non-infectious uveitis.
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: %%Member_Busname%% %%Member_Addr%% %%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%
